Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Certifies Asuragen, AltheaDx as Service Providers for Sequencing on PGM


Life Technologies has named both Asuragen and AltheaDx as authorized customer service providers for sequencing on its Ion Torrent PGM platform.

Asuragen offers targeted sequencing panels on the PGM, including its AsuraSeq custom cancer panels and the Ion AmpliSeq cancer panel, and can analyze samples from formalin-fixed paraffin-embedded tissue as well as samples collected from fine needle aspiration (CSN 1/4/2012).

AltheaDx, meantime, is using the PGM in its clinical molecular pathology laboratory for biomarker discovery and clinical trial testing, and offers sequencing services to pharmaceutical and biotechnology companies (CSN 7/6/2011).

Joe Monforte, AltheaDx's chief scientific officer, said in a statement that the company has already begun using the PGM in clinical studies and that it plans to "push ahead several of our companion diagnostic programs based on NGS."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.